Overview
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Ariel Huang, Study Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to assess the efficacy of two dose levels of brepocitinib in adults with dermatomyositis compared to a placebo. After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52-week, open-label extension phase where all participants will receive brepocitinib.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Ariel Huang, Study Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to assess the efficacy of two dose levels of brepocitinib in adults with dermatomyositis compared to a placebo. After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52-week, open-label extension phase where all participants will receive brepocitinib.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
